Dr. Ciombor on the Goals of the COLOMATE Trial in mCRC

Video

In Partnership With:

Kristen Ciombor, MD, MSCI, assistant professor of medicine, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, discusses the goals of the COLOMATE protocol in metastatic colorectal cancer (mCRC).

Kristen Ciombor, MD, MSCI, assistant professor of medicine, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, discusses the goals of the COLOMATE protocol in metastatic colorectal cancer (mCRC).

COLOMATE is an umbrella screening protocol that is seeking to match patients in academic and community centers with appropriate targeted therapy, explains Ciombor. Patients will undergo molecular profiling or liquid biopsy, and according to their profile, will be directed to an appropriate basket trial through the ACCRU network.

Currently-accruing trials include those evaluating anti-HER2, EGFR rechallenge, and anti-FGFR strategies, among others. An additional basket trial will evaluate therapies for patients without activating alterations in an attempt to identify treatments for those who have exhausted standard therapy, says Ciombor.

In addition to identifying potentially beneficial treatments, liquid biopsies can be used to monitor a patient's response to treatment over time. These tests can also detect, through circulating tumor DNA, whether the patient is responding to treatment earlier than CT scans or other imaging modalities. In the absence of response, liquid biopsies may also be able to identify mechanisms of resistance and inform additional targeted strategies, concludes Ciombor.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute